Castle Biosciences To Share New Data at DDW 2025 Highlighting TissueCypher Test's Ability To Identify Patients At Increased Risk For Developing Esophageal Cancer

Benzinga16:32 ET

New Study Shows Castle Biosciences' DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

GlobeNewswireApr 30 17:00 ET

Earnings Preview: CSTL to Report Financial Results Post-market on May 05

Moomoo NewsApr 29 21:00 ET

DecisionDx-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed With Cutaneous Melanoma

GlobeNewswireApr 28 07:00 ET

Castle Biosciences to Present Research on Melanoma Patient Care at AACR Annual Meeting 2025

Quiver QuantitativeApr 25 16:21 ET

New Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

GlobeNewswireApr 25 16:15 ET